The significance of using common two biomarkers, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) is limited in PDA management.9, 10, 11, 12 This review aims to elucidate recent advances in comprehending GATA-binding protein 6 (GATA6), emphasizing its crucial roles in both pancreas physiology and pathology. This evidence concerns the gene CEACAM5 and Patent ductus arteriosus.